GITR is expressed at low levels on resting responder T lymphocytes and is up-regulated in T regulatory cells (Treg cells) and in activated T cells, indicating that GITR is a co-stimulatory receptor and an important target for cancer immunotherapy [47]. This evidence concerns the gene TNFRSF18 and cancer.